BACKGROUND AND OBJECTIVES: Inflammatory mediators, including adipokines, have 
been studied in migraine pathophysiology; however, their role is not yet well 
established. The aim of the present study was to investigate adiponectin (ADP) 
and its association with clinical parameters and psychiatric comorbidities in 
migraine patients compared with controls.
METHODS: This was a cross sectional study including migraine patients and 
controls. Beck depression and anxiety inventories, Headache impact test, and 
Allodynia symptom checklist were recorded. Adiponectin was measured by ELISA.
RESULTS: Sixty-eight migraine patients and sixty-five controls without headache 
were included. The ADP levels were significantly higher among patients with 
migraine (43.6±11.8 versus 36.6±9.7 ng/mL, P<0.0001). Adiponectin levels were 
not correlated with depression and anxiety scores, as well as with migraine 
severity and allodynia scores.
CONCLUSION: ADP levels were raised in migraine, independently of psychiatric 
comorbidities, migraine impact, and allodynia.